Moderna Inc. (NASDAQ:MRNA) saw its shares tumble 11.3% to $67.91 by early Friday afternoon, erasing approximately $3.4 billion in market value. The stock had earlier reached a high of $78.47, marking a 13.5% decline from its intraday peak. This sharp reversal comes just a day after the European Union announced a framework agreement for up to 24 million doses of Moderna's mRESVIA respiratory syncytial virus (RSV) vaccine over four years, but crucially, the contract does not mandate any minimum purchase.
The EU deal, which involves six member countries, sets a maximum procurement ceiling but offers no guaranteed volume. The European Commission did not disclose pricing or total contract value, as the agreement establishes terms for potential future orders rather than securing a firm commitment. This distinction is critical for investors who had driven Moderna shares up 48% in June, closing Monday at $81.80—their highest since August 2024. Friday's closing price is nearly 17% below that level.
Alec Stranahan, an analyst at BofA Securities, warned that the stock had likely overshot its intrinsic value based on upcoming data readouts, seeing more downside risk. His price target of $38 is 44% below Friday's closing price, reflecting concerns about the company's near-term revenue prospects and cash burn.
The investor uncertainty is compounded by three key financial disclosures. The EU mRESVIA framework allows for up to 24 million doses but with no minimum and a four-year timeline. A separate patent settlement requires a $950 million payment, noncontingent and due by July 8, 2026. Additionally, an appeal could expose Moderna to up to $1.3 billion in further settlement costs, contingent on the outcome. The settlement filing clarifies that the $950 million is unconditional, while the additional amount depends on the appeal's result. It remains unclear whether the initial payment was made by Friday.
Moderna's cash position stands at $7.5 billion as of March 31, making the $950 million obligation equivalent to about 12.7% of that balance. The company had already recorded the expense in the first quarter and projected year-end cash and investments of $4.5 billion to $5 billion, so the deadline was known rather than a surprise charge.
The broader biotechnology market was weak but far less severe. The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) fell 2.9%, while GSK plc (NYSE:GSK) edged up 0.1% and Pfizer (NYSE:PFE) was flat. Moderna's decline was nearly four times that of the biotech fund, suggesting stock-specific selling pressure following the June rally, though no single catalyst is confirmed.
Commercially, mRESVIA has significant ground to cover. Moderna reported only $25 million in mRESVIA sales for 2024, and its 2025 revenue of $1.9 billion was predominantly from COVID-19 vaccines. In contrast, GSK's Arexvy generated £0.6 billion in 2025, and Pfizer's Abrysvo brought in $1.033 billion. The scale gap underscores the challenge Moderna faces in the RSV market.
Two key near-term events are on the horizon. Moderna is scheduled to report second-quarter results on July 31, with revenue guidance of $50 million to $100 million. The U.S. FDA has an August 5 decision target for mRNA-1010, Moderna's seasonal flu vaccine. These are firm dates, unlike the uncertain EU order timing and size.
The stock could recover if EU countries place orders quickly, the flu vaccine gains approval, or oncology data exceeds expectations. However, the downside risks are significant: the EU minimum order is zero, weak second-quarter sales could amplify cash-burn concerns, and the patent appeal could trigger up to $1.3 billion in additional settlement costs. For now, the market is focusing on firm orders and cash preservation rather than procurement ceilings. The EU agreement opens a sales channel, but it does not yet confirm how many doses will ship, when, or at what price.
